Core Viewpoint - Draganfly Inc. will host a shareholder update call on March 24, 2026, to discuss recent milestones and strategic direction, along with financial highlights [1][2]. Group 1: Company Overview - Draganfly Inc. is a leading developer of drone solutions and systems, recognized for innovation and excellence for over 25 years [4]. - The company serves various markets including public safety, civil, military, agriculture, industrial inspection, security, mapping, and surveying [4]. Group 2: Upcoming Events - The shareholder update call will be led by CEO Cameron Chell, with CFO Paul Sun reviewing key financial highlights [2]. - Quarterly financial results will be released after market close on March 24, 2026 [2]. Group 3: Investor Engagement - Investors are encouraged to submit questions in advance via email, which will be addressed during the call [3].

Company Overview - Muzero Acquisition Corp is a blank check company, also known as a special purpose acquisition company (SPAC), formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses [2] Recent Announcement - Starting March 23, 2026, holders of units sold in the Company's initial public offering can separately trade the Company's Class A ordinary shares and warrants included in the units [1] - The Class A ordinary shares and warrants will trade on the Nasdaq Stock Market under the symbols "MUZE" and "MUZEW," respectively, while units not separated will continue to trade under the symbol "MUZEU" [1]

Core Insights - Holley Performance Brands has acquired HRX, an Italian motorsports racewear brand, enhancing its capabilities in the European motorsports market [1][2][3] Group 1: Acquisition Details - The acquisition of HRX adds complementary racewear capabilities to Holley's Safety & Racing portfolio [2] - The financial terms of the transaction were not disclosed [1] Group 2: Strategic Importance - HRX has a strong presence in European racing circuits and focuses on technical racewear and customer relationships [2] - The acquisition aligns HRX's product offerings with Holley's existing safety brands, including Simpson, Stilo, HANS, and RaceQuip [2] Group 3: Leadership Statements - Holley’s CEO, Matthew Stevenson, emphasized that HRX is a strategic addition that supports the company's vision of being a leader in automotive performance solutions [3] - HRX's Managing Director, Ago Alberghino, noted that joining Holley will allow HRX to scale its capabilities and reach a broader global customer base [3]

Core Viewpoint - RenovoRx, Inc. is set to announce its fourth quarter and full year 2025 financial results and business highlights on March 30, 2026, showcasing its progress in oncology therapies and the commercialization of its FDA-cleared drug-delivery device, RenovoCath [1][4]. Group 1: Financial Results and Conference Call - The conference call will take place on March 30, 2026, at 4:30 p.m. ET, where management will discuss financial results and business highlights [1][4]. - A recording of the call will be available on the Investor Relations website, with a dial-in replay accessible until April 13, 2026 [4]. Group 2: Clinical Pipeline and Product Development - Management will provide updates on the clinical pipeline, particularly the Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, which is on track for enrollment completion in the first half of 2026, with final data expected in 2027 [3]. - The company is focusing on generating new data through post-marketing registry studies and supporting investigator-initiated trials (IIT) in pancreatic cancer, which are designed to be cost-neutral and provide meaningful data for the TAMP™ therapy platform [3]. Group 3: Commercialization Efforts - RenovoRx is in the early stages of commercializing its TAMP technology and RenovoCath, having received its first commercial purchase orders in December 2024, generating approximately $900,000 in revenue from RenovoCath sales in the first nine months of 2025 [6]. - The company is expanding its customer base, including high-volume National Cancer Institute-designated centers, and is exploring further revenue-generating activities [6]. Group 4: Product Candidates and Regulatory Status - RenovoRx is evaluating its intra-arterial gemcitabine product candidate delivered via RenovoCath in the ongoing Phase III TIGeR-PaC trial, which is regulated under a U.S. investigational new drug application [7]. - The IAG combination product candidate has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon FDA approval [8].

Core Insights - Helios Technologies has unveiled The CORE 2030 Strategy, aiming to double sales to $1.6 billion and achieve a 25%+ adjusted EBITDA margin by 2030 [1][5] - The company announced a 33% increase in its quarterly dividend to $0.12 per share, reflecting confidence in its long-term growth outlook [4][6] Financial Performance - In 2025, Helios returned to sales growth, achieving a strong fourth quarter with expanded margins [2] - The company experienced a 100 basis points year-over-year gross margin expansion and projected over $60 million in annual value from new business wins [2] - Helios has maintained a strong balance sheet, paying down approximately $158 million of debt over the past two years [3] Capital Allocation and Shareholder Returns - The company is committed to disciplined capital allocation, which includes maintaining a strong balance sheet, investing in growth, and returning capital to shareholders [3] - Helios has a track record of paying 116 consecutive quarterly dividends and has initiated share repurchases under a $100 million authorization [3] Strategic Initiatives - The CORE 2030 Strategy leverages a unique Momentum Model to drive sustainable, profitable growth and value creation for shareholders [2] - Key initiatives contributing to growth include operational excellence, go-to-market transformation, and an accelerated new product innovation pipeline, with the launch of 11 major new products [2]

Company Overview - Perma-Fix Environmental Services, Inc. is a nuclear services company specializing in nuclear and mixed waste management services, catering to hospitals, research labs, federal agencies, and the commercial nuclear industry [4]. Conference Call Announcement - The company will host a conference call on March 24, 2026, at 10:00 AM Eastern Time [1]. - The call will be accessible via telephone and webcast, with specific dialing instructions provided for U.S. and international callers [2]. - Key executives, including the CEO and CFO, will lead the conference call [2]. Webcast and Replay Information - A webcast of the call will be archived on the company's website, and a telephone replay will be available for a limited time after the call [3].

Core Insights - PureCycle Technologies, Inc. is set to participate in the 38th Annual ROTH Conference, where CEO Dustin Olson will discuss the company's global expansion plans and updates [1][2] Company Overview - PureCycle Technologies, Inc. specializes in plastic recycling, holding a global license for a patented dissolution recycling technology developed by Procter & Gamble, aimed at transforming polypropylene plastic waste into a renewable resource [3] Technology and Product - The company's unique purification process effectively removes color, odor, and impurities from polypropylene plastic waste, resulting in PureFive® resin, which can be recycled and reused multiple times [3]

Core Insights - Biodesix, Inc. announced the publication of the largest lung nodule biomarker clinical validation study, reinforcing the clinical foundation for the Nodify CDT® test as a vital decision-support tool in early lung cancer detection [1][2] Group 1: Study Findings - The study published in Future Oncology highlights that the Nodify CDT® test consistently identifies a high risk of lung cancer in patients with lung nodules sized 4-30 mm [2] - Analysis of over 1,100 patients with noncalcified lung nodules showed that the Nodify CDT test demonstrated high specificity ranging from 91% to 97%, indicating low false positive rates across various nodule sizes and patient risk factors [3] - The test's performance was validated across four distinct clinical studies involving patients from 48 clinical practices in the US, including the CLARIFY study, confirming its strong clinical applicability [3] Group 2: Clinical Implications - Dr. James Jett emphasized the need for effective decision-support tools like the Nodify CDT test to aid clinicians in managing lung nodules, as over 40% of malignant nodules can progress before definitive treatment [4] - Dr. Luke Yuhico noted that the Nodify Lung testing significantly aids decision-making in clinical practice, allowing for earlier detection of lung cancer even in small nodules [4] Group 3: Company Strategy - Scott Hutton, CEO of Biodesix, stated that the validation study supports the company's commercial expansion of the Nodify CDT test, addressing significant market opportunities in lung nodule management [4] - The consistent performance of the Nodify CDT test across real-world settings enhances the company's offerings to healthcare providers, payers, and clinical guideline committees [4]

Core Insights - Phunware, Inc. is focusing on the hospitality market and related sectors, reporting a strong cash position to accelerate its AI platform and product initiatives [1][4][10] Financial Highlights - Net revenue for FY 2025 decreased to $2.6 million from $3.2 million in FY 2024, while Q4 2025 net revenue increased by 33% to $0.8 million compared to $0.6 million in Q4 2024 [4][26] - Gross margin improved to 50.6% for FY 2025, up 500 basis points from 45.6% in FY 2024, and reached 57.7% in Q4 2025, a significant increase from 23.3% in Q4 2024 [4][26] - The net loss for FY 2025 was $11.4 million, or ($0.57) per share, compared to a net loss of $10.3 million, or ($0.94) per share in FY 2024 [4][26] - Cash and cash equivalents totaled $100.6 million as of December 31, 2025, down from $112.9 million at the end of 2024 [4][23] Recent Business Highlights - The company introduced two hospitality-specific product tiers: Luxury Engagement for premium brands and Enriched Experience for full-service independent properties, aimed at enhancing guest experiences and driving revenue [6][9] - Continued investment in AI, with a focus on guest personalization, is expected to capitalize on a trend where 50% of AI budgets in hospitality will be allocated to such efforts by 2030 [7][9] - The AI Concierge product, designed to enhance guest engagement through real-time wayfinding and personalized recommendations, is now commercially available following a successful pilot [7][9] Management Commentary - The company aims to transform the economics of large hotels and resorts through its mobile software products, emphasizing the importance of technology and AI in enhancing guest experiences and operational efficiencies [5][9] - A deliberate approach to AI development is being taken, focusing on tailored solutions that meet immediate operational needs while building robust language models for long-term value [8][9] - The leadership team has been expanded with the election of Ed Lu to the Board of Directors and the appointment of Elliot Han as Chairperson, enhancing the company's strategic direction [4][10]

Core Insights - Apple iSports Group, Inc. has appointed Ian Wilding as Fractional Chief Innovation Advisor to guide strategic innovation initiatives and support the company's transition from OTC-QB to Nasdaq listing [1][2][3] Company Overview - Apple iSports operates at the intersection of gaming infrastructure, digital entertainment, and emerging market opportunities, focusing on disciplined growth and stakeholder engagement [3][5] - The company provides gaming, wagering, and ecosystem solutions to both B2B and B2C markets [6] Leadership and Experience - Ian Wilding brings over 25 years of experience in public companies and growth-stage ventures, emphasizing strategic clarity and market insight [4][8] - Wilding's role will involve helping the leadership team make informed decisions based on real market signals and ensuring the company meets Nasdaq standards [5][4] Strategic Focus - The appointment of Wilding reflects Apple iSports' commitment to disciplined growth and operating at the standards expected of leading public companies [5] - The management team has over four decades of experience in regulated markets, which will be leveraged as the company expands into the U.S. market [7]